Claims for Patent: 9,709,575

Summary for Patent: 9,709,575

Title:	Methods and products for evaluating an immune response to a therapeutic protein
Abstract:	The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titer of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titer of untreated patients increased by the double of the standard deviation of this control antibody titer.
Inventor(s):	Subramanyam; Meena (Stoneham, MA), Amaravadi; Lakshmi (Natick, MA), Wakshull; Eric (Princeton, MA), Lynn; Frances (Somerville, MA), Panzara; Michael (Winchester, MA), Barbour; Robin McDaid (Walnut Creek, CA), Taylor; Julie Elizabeth (San Francisco, CA)
Assignee:	Biogen MA Inc. (Cambridge, MA)
Application Number:	14/330,619
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,709,575
Patent Claims:	1. A method comprising: administering natalizumab to a subject; and detecting whether at least a threshold level of anti-natalizumab antibody binding activity is present in a biological sample obtained from the subject, wherein the threshold level is equal to the level of anti-natalizumab antibody binding activity present in a reference sample comprising at least 500 ng/ml of anti-natalizumab antibody. 2. The method of claim 1, wherein the level of anti-natalizumab antibody binding activity is measured in a first aliquot of the biological sample, and wherein the method further comprises determining the binding specificity of the anti-natalizumab antibody for natalizumab. 3. The method of claim 2, wherein the binding specificity of the anti-natalizumab antibody is determined in a second aliquot of the biological sample. 4. The method of claim 1, wherein the level of anti-natalizumab antibody binding activity is determined by comparing levels of binding to a labeled VLA-4 binding antibody measured in the presence of two or more different amounts of unlabeled VLA-4 binding antibody. 5. The method of claim 1, wherein the level of anti-natalizumab antibody is determined by comparing levels of binding to an immobilized VLA-4 binding antibody measured in the presence of two or more different amounts of soluble VLA-4 binding antibody. 6. The method of claim 1, wherein the level of anti-natalizumab antibody binding activity is determined by comparing a first level of binding to a labeled VLA-4 binding antibody measured in the presence of a first amount of unlabeled VLA-4 binding antibody to a second level of binding to a labeled VLA-4 binding antibody measured in the presence of a second amount of unlabeled VLA-4 binding antibody. 7. The method of claim 1, wherein the subject is a human subject. 8. The method of claim 1, wherein the subject has multiple sclerosis, rheumatoid arthritis, or Crohn's disease. 9. The method of claim 1, wherein biological sample is a serum sample. 10. The method of claim 1, further comprising modifying natalizumab treatment of the subject if the threshold level of anti-natalizumab antibody binding activity is present in the biological sample from the subject. 11. The method of claim 10, wherein modifying natalizumab treatment of the subject comprises discontinuing treatment of the subject with natalizumab, altering the dose amount of natalizumab that is administered to the subject, altering the frequency at which natalizumab is administered to the subject, altering the route by which natalizumab is administered to the subject, altering duration of the treatment of the subject with natalizumab, combining natalizumab treatment with one or more additional treatments, or treating the subject with a different VLA-4-binding antibody. 12. The method of claim 1, further comprising continuing with treatment of the subject with natalizumab if the threshold level of anti-natalizumab antibody binding activity is not present in the biological sample from the subject. 13. The method of claim 1, wherein the detecting comprises performing an antibody detection assay. 14. The method of claim 13, wherein the antibody detection assay is performed on two or more biological samples taken from the subject at different time points. 15. The method of claim 14, wherein the different time points are separated by at least one month. 16. The method of claim 13, wherein the antibody detection assay is a bridging ELISA assay.

Details for Patent 9,709,575

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	11/23/2004		2025-04-04